![]() Therefore, you should not rely on any of these forward-looking statements. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Instead, they are based only on CHAC and BiomX managements' current beliefs, expectations and assumptions. Forward-looking statements are neither historical facts nor assurances of future performance. Examples of forward-looking statements include, among others, statements made in this press release regarding the proposed business combination, including the anticipated initial enterprise value and post-closing equity value, the benefits of the proposed business combination, integration plans, expected synergies and revenue opportunities, anticipated future financial and operating performance and results, including estimates for growth, the expected management and governance of the combined company, and the expected timing of the proposed transactions contemplated by the definitive agreement. Forward-looking statements can be identified by words such as: "target," "believe," "expect," "will," "may," "anticipate," "estimate," "would," "positioned," "future," and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. This press release contains certain "forward-looking statements" within the meaning of the "safe harbor" provisions of the US Private Securities Litigation Reform Act of 1995. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets. CHAC is Chardan's fifth publicly traded acquisition vehicle.īiomX is a microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as IBD, PSC, and cancer. ![]() CHAC was founded and sponsored by affiliates of Chardan. CHAC raised $70.0 million in December 2018 for the purpose of combining with a public or privately-held operating business.
0 Comments
Leave a Reply. |